218 Einträge | « ‹ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 › » |
Seite 4 / 11
![]() |
Vienna international summer school on experimental and clinical oncology for medical students: an Austrian cancer education project. |
Fromm-Haidenberger S, Pohl G, Widder J, Kren G, Fitzal F, Bartsch R, de Vries J, Zielinski C, Pötter R |
Journal of cancer education : the official journal of the American Association for Cancer Education. 2010 Apr 1. doi: 10.1007/s13187-009-0011-3 |
PMID: 20082180 |
Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer. |
Bartsch R, De Vries C, Pluschnig U, Dubsky P, Bago-Horvath Z, Gampenrieder SP, Rudas M, Mader RM, Rottenfusser A, Wiltschke C, Gnant M, Zielinski CC, Steger GG |
BMC cancer. 2009 Oct 17. pii: 1471-2407-9-367. doi: 10.1186/1471-2407-9-367. pmc: PMC2770076 |
PMID: 19835621 |
Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. |
Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Nader A, Stierer M, Gnant MF |
Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Sep 1. pii: 1078-0432.CCR-09-0728. doi: 10.1158/1078-0432.CCR-09-0728 |
PMID: 19723645 |
Role of denosumab in breast cancer. |
Bartsch R, Steger GG |
Expert opinion on biological therapy. 2009 Aug 5. doi: 10.1517/14712590903146877 |
PMID: 19653867 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. |
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R, Marth C |
The New England journal of medicine. 2009 Feb 13. pii: 360/7/679. doi: 10.1056/NEJMoa0806285 |
PMID: 19213681 |
The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools. |
Bartsch R, Steger GG |
Breast care (Basel, Switzerland). 2009 Jun 23. doi: 10.1159/000223360. pmc: PMC2931004. pii: 223360 |
PMID: 20847876 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. |
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R |
The Lancet. Oncology. 2008 Aug 19. pii: S1470-2045(08)70204-3. doi: 10.1016/S1470-2045(08)70204-3 |
PMID: 18718815 |
The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer. |
Bartsch R, Mlineritsch B, Gnant M, Niernberger T, Pluschnig U, Greil R, Wenzel C, Sevelda P, Thaler J, Rudas M, Pober M, Zielinski CC, Steger GG |
Breast cancer research and treatment. 2008 Jul 26. doi: 10.1007/s10549-008-0132-0 |
PMID: 18661231 |
Factors influencing the time to development of brain metastases in breast cancer. |
Fromm S, Bartsch R, Rudas M, de Vries A, Wenzel C, Steger GG, Zielinski CC, Poetter R, Dieckmann K |
Breast (Edinburgh, Scotland). 2008 May 19. pii: S0960-9776(08)00102-1. doi: 10.1016/j.breast.2008.03.008 |
PMID: 18486473 |
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. |
Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M |
Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Apr 2. pii: 14/7/2082. doi: 10.1158/1078-0432.CCR-07-2068 |
PMID: 18381948 |
Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. |
Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M |
Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Mar 18. pii: 14/6/1767. doi: 10.1158/1078-0432.CCR-07-4122 |
PMID: 18347178 |
Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. |
Bartsch R, Wenzel C, Gampenrieder SP, Pluschnig U, Altorjai G, Rudas M, Mader RM, Dubsky P, Rottenfusser A, Gnant M, Zielinski CC, Steger GG |
Cancer chemotherapy and pharmacology. 2008 Feb 7. doi: 10.1007/s00280-008-0682-1 |
PMID: 18256835 |
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. |
Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Rudas M, Mader RM, Gnant M, Zielinski CC, Steger GG |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Aug 6. pii: JCO.2007.11.9776. doi: 10.1200/JCO.2007.11.9776 |
PMID: 17679724 |
Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment. |
Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Mader RM, Gnant M, Jakesz R, Rudas M, Zielinski CC, Steger GG |
Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Aug 2. pii: 13/15/4435. doi: 10.1158/1078-0432.CCR-06-3050 |
PMID: 17671127 |
Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel. |
Bartsch R, Steger GG, Forstner B, Wenzel C, Pluschnig U, Rizovski B, Altorjai G, Zielinski CC, Mader RM |
BMC clinical pharmacology. 2007 Jul 18. pii: 1472-6904-7-7. doi: 10.1186/1472-6904-7-7. pmc: PMC1939983 |
PMID: 17640356 |
Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. |
Bartsch R, Rottenfusser A, Wenzel C, Dieckmann K, Pluschnig U, Altorjai G, Rudas M, Mader RM, Poetter R, Zielinski CC, Steger GG |
Journal of neuro-oncology. 2007 Jun 8. doi: 10.1007/s11060-007-9420-5 |
PMID: 17557136 |
HER-2-positive breast cancer: hope beyond trastuzumab. |
Bartsch R, Wenzel C, Zielinski CC, Steger GG |
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2007 Apr 3. pii: 2121 |
PMID: 17402790 |
Trastuzumab in the management of early and advanced stage breast cancer. |
Bartsch R, Wenzel C, Steger GG |
Biologics : targets & therapy. 2009 Aug 26. pmc: PMC2721347 |
PMID: 19707345 |
Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF. |
Wenzel C, Bartsch R, Hussian D, Pluschnig U, Altorjai G, Zielinski CC, Lang A, Haid A, Jakesz R, Gnant M, Steger GG |
Breast cancer research and treatment. 2006 Oct 24. doi: 10.1007/s10549-006-9397-3 |
PMID: 17061042 |
Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. |
Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Bachleitner-Hoffmann T, Locker GJ, Rudas M, Mader R, Zielinski CC, Steger GG |
Breast cancer research and treatment. 2006 Sep 21. doi: 10.1007/s10549-006-9342-5 |
PMID: 17028979 |
218 Einträge | « ‹ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 › » |
Seite 4 / 11
![]() |